Search for: "Watson v. US" Results 401 - 420 of 919
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Sep 2019, 9:30 pm by ernst
Civil Rights Commission, and the author, most recently, of History Teaches Us to Resist: How Progressive Movements Have Succeeded in Challenging Times, will help lead “an ‘organizing for change’ panel discussion September 22 at the Milford Theater, 114 Catherine St., Milford, [PA]. [read post]
25 Jan 2018, 4:58 am by Jon Gelman
Watson v 84 Lumber CP 2009-15740 (NJ DWC 2016) Decided: 12.15.2016“One of the primary benefits under the Workers' Compensation Act is that of medical benefits. [read post]
13 Feb 2009, 5:00 am
(Profitability through Simplicity) Patent World SPC round-up ‘Prolonging Patent Protection’ by Marjan Noor (SPC Blog) EU: Commission’s view on paediatric extensions (The SPC Blog) EU: Suing, not suing both attract the Commission’s attention – EU pharma inquiry (PatLit) EU: Life Science marks held confusingly similar: Bayern Innovativ – Bayerische Gesellschaft für Innovation und Wissenstransfer mbH, v Office for… [read post]
9 Dec 2009, 3:59 pm
Watson Laboratories Inc. - Florida et al  (Patent Docs) Surfaxin (Lucinactant) – US: PTO rules on the availability of multiple interim patent extensions (FDA Law Blog) Taxotere (Docetaxel) – Canada: Federal Court refuses to grant Order of Prohibition against Hospira regarding Docetaxel product: Sanofi v Hospira (Pharmacapsules @ Gowlings) Vigamox (Moxifloxacin) – US: Teva appeals verdict finding ANDA to market generic Vigamox infringes… [read post]
16 Mar 2017, 5:12 am by SHG
In a dissent to the Ninth Circuit’s refusal to rehear Washington v. [read post]
30 Jan 2018, 10:43 am by James Reid
“And the visual recognition and photo tagging is the same technology we use to help radiologists spot cancer. [read post]
12 Oct 2011, 3:46 am by Marie Louise
No (FDA Law Blog) US: Patent battle over modified meganucleases heats up: Cellectis v Precision Biosciences (Holman’s Biotech IP Blog) (Patent Docs) US: Landmark NORD report on orphan drugs authored by HP&M Director shows FDA flexibility in approval (FDA Law Blog)   Products Embeda (Morphine sulfate, Naltrexone hydrochloride) – US: Pfizer, Alpharma, King Pharma. file patent infringement suit against Watson following Para IV… [read post]
17 Mar 2008, 1:31 pm
Watson, The Decay of "Divers" and the Future of Charging "Under Divers Occasions" in Light of United States v. [read post]
2 Feb 2007, 12:29 am
Charles Watson BRONX COUNTYInsurance LawMVAIC Denied Dismissal of No-Fault Benefits Request; Claims Received Within Statutory Period Bronx Expert Radiology PC v. [read post]
18 Mar 2010, 2:30 am
: The Medicines Company v David Kappos et al (FDA Law Blog) Advate (Antihemophilic) – US: False marking complaint filed in N D Illinois: Simonian v. [read post]
13 Aug 2021, 4:00 am by Jim Sedor
Rick Scott unlawfully used a super PAC to support his 2018 Senate run. [read post]
11 Nov 2009, 4:02 am
: Bilski (IP Frontline) US: Next up: Ariad v Lilly rehearing en banc (Patent Docs) Products Ablify (Aripiprazole) - US: Otsuka files patent infringement suit against Teva in response to Para IV challenge (Patent Docs) Boniva (Ibandronic acid) - US: Roche drops two lawsuits in response to Teva cancelling plans to manufacture generic Boniva (The IP Factor) Copaxone (Glatiramer) - US: Teva files amended complaint against Momenta/Sandoz to include… [read post]